|
1
|
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
|
J Clin Oncol
|
1999
|
10.86
|
|
2
|
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
|
J Clin Oncol
|
2001
|
4.97
|
|
3
|
High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.
|
Blood
|
1992
|
2.14
|
|
4
|
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
|
Cancer J Sci Am
|
1997
|
1.45
|
|
5
|
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission.
|
Leukemia
|
1999
|
1.26
|
|
6
|
Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.
|
J Clin Oncol
|
2001
|
1.16
|
|
7
|
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
|
J Clin Oncol
|
1993
|
1.16
|
|
8
|
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.
|
J Clin Oncol
|
1989
|
1.04
|
|
9
|
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
|
Biol Blood Marrow Transplant
|
2003
|
1.03
|
|
10
|
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.
|
Med Oncol
|
2001
|
1.03
|
|
11
|
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
|
Cancer J Sci Am
|
1997
|
0.97
|
|
12
|
Thalidomide as salvage therapy for chronic graft-versus-host disease.
|
Blood
|
1995
|
0.96
|
|
13
|
Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
|
Clin Lymphoma
|
2000
|
0.95
|
|
14
|
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
|
J Clin Oncol
|
1990
|
0.95
|
|
15
|
Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
|
Clin Cancer Res
|
2000
|
0.94
|
|
16
|
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
|
Blood
|
1999
|
0.92
|
|
17
|
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.
|
Blood
|
1997
|
0.92
|
|
18
|
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
|
Biol Blood Marrow Transplant
|
2003
|
0.91
|
|
19
|
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
|
J Clin Oncol
|
1997
|
0.88
|
|
20
|
Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
|
Cancer J Sci Am
|
1997
|
0.88
|
|
21
|
Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.
|
Invest New Drugs
|
1995
|
0.88
|
|
22
|
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
|
J Clin Oncol
|
1995
|
0.84
|
|
23
|
Fibromyalgia and interleukin-2 therapy for malignancy.
|
Ann Intern Med
|
1988
|
0.84
|
|
24
|
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
|
Med Oncol
|
2001
|
0.84
|
|
25
|
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer.
|
Br J Cancer
|
2002
|
0.82
|
|
26
|
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
|
Clin Cancer Res
|
1997
|
0.82
|
|
27
|
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
|
Blood
|
1997
|
0.82
|
|
28
|
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
|
J Clin Oncol
|
2001
|
0.82
|
|
29
|
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
|
Gynecol Oncol
|
1995
|
0.82
|
|
30
|
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
|
Cancer Res
|
1998
|
0.81
|
|
31
|
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
|
J Clin Oncol
|
1986
|
0.80
|
|
32
|
Lidocaine for severe hiccups.
|
N Engl J Med
|
1993
|
0.80
|
|
33
|
5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.
|
Cancer Invest
|
1995
|
0.79
|
|
34
|
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
|
J Immunother Emphasis Tumor Immunol
|
1994
|
0.78
|
|
35
|
Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.
|
J Cancer Res Clin Oncol
|
1995
|
0.78
|
|
36
|
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
|
Int J Gynecol Cancer
|
2007
|
0.78
|
|
37
|
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
|
NCI Monogr
|
1987
|
0.77
|
|
38
|
Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.
|
J Cancer Res Clin Oncol
|
1992
|
0.77
|
|
39
|
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
|
Adv Exp Med Biol
|
1988
|
0.76
|
|
40
|
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
|
Biol Blood Marrow Transplant
|
2001
|
0.76
|
|
41
|
Mechanism of mitochondrial DNA replication in mouse L cells: localization of alkali-sensitive sites at the two origins of replication.
|
Plasmid
|
1981
|
0.76
|
|
42
|
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.
|
Cancer Invest
|
1999
|
0.75
|
|
43
|
Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.
|
Am J Med
|
1987
|
0.75
|
|
44
|
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
|
Biol Blood Marrow Transplant
|
2012
|
0.75
|
|
45
|
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
|
Clin Cancer Res
|
2001
|
0.75
|
|
46
|
Fluorouracil and leucovorin in advanced breast cancer.
|
Adv Exp Med Biol
|
1993
|
0.75
|
|
47
|
High-titer, high-thermal-amplitude cold autoagglutinin not associated with hemolytic anemia.
|
Vox Sang
|
1988
|
0.75
|
|
48
|
Possible mechanism of interleukin-2-induced decline of serum cholesterol during adoptive cellular immunotherapy in cancer patients.
|
Biochem Med Metab Biol
|
1993
|
0.75
|
|
49
|
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
|
Gynecol Oncol
|
1999
|
0.75
|
|
50
|
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
|
Bone Marrow Transplant
|
2001
|
0.75
|
|
51
|
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
|
J Clin Oncol
|
1989
|
0.75
|
|
52
|
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy.
|
Cancer Chemother Pharmacol
|
2001
|
0.75
|
|
53
|
Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.
|
Invest New Drugs
|
1991
|
0.75
|
|
54
|
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
|
Gynecol Oncol
|
2000
|
0.75
|
|
55
|
Apheresis techniques in lymphokine-activated killer cell production.
|
J Clin Apher
|
1988
|
0.75
|
|
56
|
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
|
Ann Oncol
|
2015
|
0.75
|
|
57
|
Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
|
Med Pediatr Oncol
|
1990
|
0.75
|